Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Precision Optics (NASDAQ:POCI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Valuation & Earnings
This table compares Lucid Diagnostics and Precision Optics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 45.92 | -$58.01 million | ($0.47) | -2.27 |
| Precision Optics | $19.09 million | 3.28 | -$5.78 million | ($0.63) | -9.08 |
Profitability
This table compares Lucid Diagnostics and Precision Optics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -876.72% | N/A | -116.26% |
| Precision Optics | -17.03% | -37.47% | -19.96% |
Analyst Recommendations
This is a summary of current ratings and price targets for Lucid Diagnostics and Precision Optics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Precision Optics | 1 | 0 | 0 | 0 | 1.00 |
Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 293.19%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Precision Optics.
Volatility and Risk
Lucid Diagnostics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Insider and Institutional Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 13.7% of Precision Optics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 14.4% of Precision Optics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Lucid Diagnostics beats Precision Optics on 9 of the 14 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Precision Optics
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
